Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Hospitals Can Adapt to Supply Chain Disruptions

COVID-19 has brought increasingly disruptive ripple effects across each of the world’s industries, but healthcare has been hit particularly hard. In addition to managing the increased stressors associated directly with the pandemic, healthcare providers the world over are dealing with the fallout of severe disruptions throughout their supply chains. In uncertain periods such as this,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
How Hospitals Can Adapt to Supply Chain Disruptions

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

COVID-19 has brought increasingly disruptive ripple effects across each of the world’s industries, but healthcare has been hit particularly hard.

In addition to managing the increased stressors associated directly with the pandemic, healthcare providers the world over are dealing with the fallout of severe disruptions throughout their supply chains.

In uncertain periods such as this, TPC stands ready to assist its Member hospitals in finding agile solutions to these disruptions that allow operations to remain as close to normal as possible as we collectively work through the challenges set in front of us.

As COVID-19 Proves, Healthcare Providers Must Be Ready to Pivot at a Moment’s Notice

Though COVID-19 is far from the first disruptive force healthcare supply chains have been asked to navigate, it has presented some unique challenges.

It’s more important than ever to evaluate best practices in adapting and responding to these disruptions.

First, it’s critical to thoroughly review not only your own supply chain, but the state of key drugs, other products, and their manufacturers. The FDA has been diligent in working with manufacturers of both drugs and medical equipment to get an idea of exactly how disruptive this pandemic might be, and it’s important that you leverage that information as often as you can to formulate a plan of attack that addresses potential impacts on your own supply chain.

Proactive risk management plans, data sharing and collaboration can ensure you’re firmly on the front line in fighting these disruptions and continuing to provide the key services and quality care for your patients.

Several best practices have also been recommended during this pandemic, including:

  • Providing education regarding COVID-19 to staff.
  • Rationing masks and personal protective equipment and curtailing areas where these products are available for use.
  • Managing N-95 mask usage and creating a proactive plan regarding nurses who will use the masks, careful attention to reuse guidelines, and more.

TPC is Proud to Help Guide You Through Uncertainty

As uncertainty mounts in the face of these supply chain disruptions, TPC is, as always, committed to acting as your guide toward proactive, beneficial action and working to source new suppliers and evaluate innovative solutions to assist our Members in their time of need.

With TPC’s ongoing commitment to communication and support, you can be confident in your ability to navigate these temporary disruptions and continue providing the best possible care to your patients.

Disruptions are going to occur, and COVID-19 is far from the last – however, by being flexible in addressing these challenges, we can work together to find solutions, providing valuable support within the TPC Member family.

To learn more or reach out with any specific questions, visit tpc1.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512